These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

894 related items for PubMed ID: 30814356

  • 1. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y, Nakamura T, Kawarabayashi T, Hirohata M, Narita S, Wakasaya Y, Kaito K, Ueda T, Harigaya Y, Shoji M.
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [Abstract] [Full Text] [Related]

  • 2. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 3. Correlation between Cerebrospinal Fluid Core Alzheimer's Disease Biomarkers and β-Amyloid PET in Chinese Dementia Population.
    Xie Q, Ni M, Gao F, Dai LB, Lv XY, Zhang YF, Shi Q, Zhu XX, Xie JK, Shen Y, Wang SC.
    ACS Chem Neurosci; 2022 May 18; 13(10):1558-1565. PubMed ID: 35476397
    [Abstract] [Full Text] [Related]

  • 4. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A, Al-Grety A, Carlsson H, Patra K, Twohig D, Sando SB, Lauridsen C, Berge G, Grøntvedt GR, Bråthen G, White LR, Kultima K, Nielsen HM.
    Alzheimers Res Ther; 2022 Aug 24; 14(1):115. PubMed ID: 36002891
    [Abstract] [Full Text] [Related]

  • 5. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
    Seeburger JL, Holder DJ, Combrinck M, Joachim C, Laterza O, Tanen M, Dallob A, Chappell D, Snyder K, Flynn M, Simon A, Modur V, Potter WZ, Wilcock G, Savage MJ, Smith AD.
    J Alzheimers Dis; 2015 Aug 24; 44(2):525-39. PubMed ID: 25391385
    [Abstract] [Full Text] [Related]

  • 6. PTI-125 Reduces Biomarkers of Alzheimer's Disease in Patients.
    Wang HY, Pei Z, Lee KC, Lopez-Brignoni E, Nikolov B, Crowley CA, Marsman MR, Barbier R, Friedmann N, Burns LH.
    J Prev Alzheimers Dis; 2020 Aug 24; 7(4):256-264. PubMed ID: 32920628
    [Abstract] [Full Text] [Related]

  • 7. Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
    Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.
    Curr Clin Pharmacol; 2008 May 24; 3(2):123-31. PubMed ID: 18700307
    [Abstract] [Full Text] [Related]

  • 8. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
    Moon S, Kim S, Mankhong S, Choi SH, Vandijck M, Kostanjevecki V, Jeong JH, Yoon SJ, Park KW, Kim EJ, Yoon B, Kim HJ, Jang JW, Hong JY, Park DH, Shaw LM, Kang JH.
    Alzheimers Res Ther; 2021 Jan 12; 13(1):22. PubMed ID: 33436035
    [Abstract] [Full Text] [Related]

  • 9. Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer's Disease Using Quantitative Systems Pharmacology Model.
    Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P, Tolar M.
    Drugs; 2024 Jul 12; 84(7):825-839. PubMed ID: 38902572
    [Abstract] [Full Text] [Related]

  • 10. Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study.
    Abu-Rumeileh S, Giannini G, Polischi B, Albini-Riccioli L, Milletti D, Oppi F, Stanzani-Maserati M, Capellari S, Mantovani P, Palandri G, Cortelli P, Cevoli S, Parchi P.
    J Alzheimers Dis; 2019 Jul 12; 68(2):723-733. PubMed ID: 30883350
    [Abstract] [Full Text] [Related]

  • 11. Differential levels of alpha-synuclein, beta-amyloid42 and tau in CSF between patients with dementia with Lewy bodies and Alzheimer's disease.
    Kasuga K, Tokutake T, Ishikawa A, Uchiyama T, Tokuda T, Onodera O, Nishizawa M, Ikeuchi T.
    J Neurol Neurosurg Psychiatry; 2010 Jun 12; 81(6):608-10. PubMed ID: 20522869
    [Abstract] [Full Text] [Related]

  • 12. CSF Aβ42 and Aβ42/Aβ40 Ratio in Alzheimer's Disease and Frontotemporal Dementias.
    Constantinides VC, Paraskevas GP, Boufidou F, Bourbouli M, Pyrgelis ES, Stefanis L, Kapaki E.
    Diagnostics (Basel); 2023 Feb 19; 13(4):. PubMed ID: 36832271
    [Abstract] [Full Text] [Related]

  • 13. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.
    Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675
    [Abstract] [Full Text] [Related]

  • 14. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E, Su Y, Chen Y, Serrano GE, Leuzy A, Mattsson-Carlgren N, Strandberg O, Smith R, Villegas A, Sepulveda-Falla D, Chai X, Proctor NK, Beach TG, Blennow K, Dage JL, Reiman EM, Hansson O.
    JAMA; 2020 Aug 25; 324(8):772-781. PubMed ID: 32722745
    [Abstract] [Full Text] [Related]

  • 15. Lower Left Ventricular Ejection Fraction Relates to Cerebrospinal Fluid Biomarker Evidence of Neurodegeneration in Older Adults.
    Kresge HA, Liu D, Gupta DK, Moore EE, Osborn KE, Acosta LMY, Bell SP, Pechman KR, Gifford KA, Mendes LA, Wang TJ, Blennow K, Zetterberg H, Hohman TJ, Jefferson AL.
    J Alzheimers Dis; 2020 Aug 25; 74(3):965-974. PubMed ID: 32144980
    [Abstract] [Full Text] [Related]

  • 16. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L, Peters O, Lewczuk P, Gruber O, Teipel SJ, Gertz HJ, Jahn H, Jessen F, Kurz A, Luckhaus C, Hüll M, Pantel J, Reischies FM, Schröder J, Wagner M, Rienhoff O, Wolf S, Bauer C, Schuchhardt J, Heuser I, Rüther E, Henn F, Maier W, Wiltfang J, Kornhuber J.
    Alzheimers Res Ther; 2017 Oct 10; 9(1):84. PubMed ID: 29017593
    [Abstract] [Full Text] [Related]

  • 17. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.
    Parkinsonism Relat Disord; 2015 Jul 10; 21(7):758-64. PubMed ID: 25971633
    [Abstract] [Full Text] [Related]

  • 18. Differential associations of clinical features with cerebrospinal fluid biomarkers in dementia with Lewy bodies and Alzheimer's disease.
    de Oliveira FF, Miraldo MC, de Castro-Neto EF, de Almeida SS, Matas SLA, Bertolucci PHF, Naffah-Mazzacoratti MDG.
    Aging Clin Exp Res; 2023 Aug 10; 35(8):1741-1752. PubMed ID: 37264166
    [Abstract] [Full Text] [Related]

  • 19. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.
    Mov Disord; 2011 Jul 10; 26(8):1428-35. PubMed ID: 21469206
    [Abstract] [Full Text] [Related]

  • 20. The added value of Aβ42/Aβ40 in the CSF signature for routine diagnostics of Alzheimer's disease.
    Biscetti L, Salvadori N, Farotti L, Cataldi S, Eusebi P, Paciotti S, Parnetti L.
    Clin Chim Acta; 2019 Jul 10; 494():71-73. PubMed ID: 30844364
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.